Circulating microRNAs improve bacterial infection diagnosis and overall survival prediction in acute decompensation of liver cirrhosis

Archive ouverte

Chouik, Yasmina | Lebossé, Fanny | Plissonnier, Marie‐laure | Lega, Jean-Christophe | Pradat, Pierre | Antonini, Teresa | Subic, Miroslava | Hartig-Lavie, Kerstin | Erard, Domitille | Villeret, François | Guichon, Céline | Payancé, Audrey | Radenne, Sylvie | Rautou, Pierre-Emmanuel | Zoulim, Fabien | Levrero, Massimo

Edité par CCSD ; Elsevier -

International audience. Bacterial infections are the most frequent precipitating event in patients with acute decompensation of cirrhosis (AD) and are associated with high mortality. Early diagnosis is challenging due to cirrhosis-related systemic inflammation. Here we investigated the potential of circulating microRNAs to diagnose bacterial infections and predict survival in cirrhotic patients with AD. High throughput profiling of circulating microRNAs was performed using the Nanostring technology in 57 AD patients and 24 patients with compensated cirrhosis (CC). Circulating miRs profiling showed that: (a) miRs differentially detected in AD vs. CC were mostly down-regulated; (b) a composite score including absolute neutrophil count, C reactive protein and miR-362-3p could diagnose bacterial infection with an excellent performance (AUC of 0.825 [95% CI = 0.671–0.980; p < 0.001]); (c) a composite score including miR-382-5p, miR-592 and MELD-Na improved 6-month survival prediction. Circulating miRs are strongly dysregulated in patients with AD and may help to improve bacterial infection diagnosis and survival prediction.

Suggestions

Du même auteur

Circulating microRNAs improve bacterial infection diagnosis and overall survival prediction in acute decompensation of liver cirrhosis

Archive ouverte | Chouik, Yasmina | CCSD

International audience

Circulating microRNAs improve bacterial infection diagnosis and overall survival prediction in acute decompensation of liver cirrhosis

Archive ouverte | Chouik, Yasmina | CCSD

International audience

Direct-acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C

Archive ouverte | Virlogeux, Victor | CCSD

International audience. BACKGROUND AND AIMS: Arrival of direct-acting antiviral (DAA) agents against hepatitis C virus (HCV) with high-sustained virological response (SVR) rates and very few side effects has drastic...

Chargement des enrichissements...